Skip to main content

Table 3 Costs, QALY and net monetary benefit results from 10-year time horizon scenario

From: Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis

  Combination therapy 5-ARI α-blockers FT
Price $11,000 Price $4500
Costs per patient ($) 1453.10 1558.71 1571.75 12,043.58 5570.97
QALY per patient 4.20 4.20 4.20 4.27 4.28
Willingness-to-pay threshold at $150,000      
Net Monetary Benefit (NMB) ($) 628,546.90 628,441.29 628,428.25 628,456.42 636,429.03
Willingness-to-pay threshold at $50,000      
Net Monetary Benefit (NMB) ($) 208,546.90 208,441.29 208,428.25 201,456.42 208,429.03
  1. QALY quality-adjusted life years, 5-ARI 5-α-Reductase inhibitors, FT Fexapotide triflutate